Innate Pharma SA
IPHANasdaqCIK 1598599HealthcareFiscal year ends Dec 31
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-12-31 | FY20222022-12-31 | FY20232023-12-31 | FY20242024-12-31 | FY20252025-12-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $m | 24.7Revenue, FY2021, twelve months to 2021-12-31EUR 24.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-04-04, accession 0001598599-24-000020.Report this figure | 57.7Revenue, FY2022, twelve months to 2022-12-31EUR 57.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001598599-25-000042.Report this figure | 61.6Revenue, FY2023, twelve months to 2023-12-31EUR 61.6m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | 20.1Revenue, FY2024, twelve months to 2024-12-31EUR 20.1m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | 9.0Revenue, FY2025, twelve months to 2025-12-31EUR 9.0m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | (193.6%)Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: −EUR 47.8m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-04-04, accession 0001598599-24-000020.Revenue: EUR 24.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-04-04, accession 0001598599-24-000020.Report this figure | (99.6%)Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: −EUR 57.4m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-04-30, accession 0001598599-25-000042.Revenue: EUR 57.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001598599-25-000042.Report this figure | (20.6%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −EUR 12.7m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Revenue: EUR 61.6m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (256.3%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −EUR 51.6m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Revenue: EUR 20.1m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (599.8%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −EUR 54.0m. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Revenue: EUR 9.0m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | |
| Net margin | % | (213.8%)Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: −EUR 52.8m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2024-04-04, accession 0001598599-24-000020.Revenue: EUR 24.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2024-04-04, accession 0001598599-24-000020.Report this figure | (100.7%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −EUR 58.1m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2025-04-30, accession 0001598599-25-000042.Revenue: EUR 57.7m. XBRL concept ifrs-full:Revenue. 20-F filed 2025-04-30, accession 0001598599-25-000042.Report this figure | (12.3%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −EUR 7.6m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2026-04-01, accession 0001598599-26-000005.Revenue: EUR 61.6m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (245.9%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −EUR 49.5m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2026-04-01, accession 0001598599-26-000005.Revenue: EUR 20.1m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (546.1%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −EUR 49.2m. XBRL concept ifrs-full:ProfitLoss. 20-F filed 2026-04-01, accession 0001598599-26-000005.Revenue: EUR 9.0m. XBRL concept ifrs-full:Revenue. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | |
| Diluted EPS | $ per share | (0.66)Diluted EPS, FY2021, twelve months to 2021-12-31−EUR 0.66 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-04-04, accession 0001598599-24-000020.Report this figure | (0.73)Diluted EPS, FY2022, twelve months to 2022-12-31−EUR 0.73 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-04-30, accession 0001598599-25-000042.Report this figure | (0.09)Diluted EPS, FY2023, twelve months to 2023-12-31−EUR 0.09 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (0.61)Diluted EPS, FY2024, twelve months to 2024-12-31−EUR 0.61 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (0.55)Diluted EPS, FY2025, twelve months to 2025-12-31−EUR 0.55 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | |
| Free cash flow | $m | (59.4)Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 58.5m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-04-04, accession 0001598599-24-000020.Capital expenditure: EUR 929.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-04-04, accession 0001598599-24-000020.Report this figure | (19.7)Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 19.2m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-04-30, accession 0001598599-25-000042.Capital expenditure: EUR 535.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-04-30, accession 0001598599-25-000042.Report this figure | (32.9)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 32.6m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Capital expenditure: EUR 351.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (7.3)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 6.9m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Capital expenditure: EUR 391.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure | (52.9)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −EUR 52.8m. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Capital expenditure: EUR 140.0k. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2026-04-01, accession 0001598599-26-000005.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Lion Point Capital, LP | 2026-06-30 | $149.3k | 81,151 | Unchanged | |
| MORGAN STANLEY | 2026-06-30 | $80.1k | 43,524 | Unchanged | |
| SmartHarvest Portfolios, LLC | 2026-06-30 | $43.7k | 23,750 | New+23,750 | |
| XTX Topco Ltd | 2026-06-30 | $27.8k | 15,130 | New+15,130 | |
| CITADEL ADVISORS LLC | 2026-06-30 | $22.9k | 12,441 | New+12,441 | |
| JANE STREET GROUP, LLC | 2026-06-30 | $19.0k | 10,310 | Reduced−33,055 | |
| RHUMBLINE ADVISERS | 2026-06-30 | $8.7k | 4,719 | Reduced−15 | |
| UBS Group AG | 2026-06-30 | $2.5k | 1,363 | Added+502 | |
| Farther Finance Advisors, LLC | 2026-06-30 | $38 | 21 | Added+11 | |
| GAMMA Investing LLC | 2026-06-30 | $17 | 9 | Reduced−231 |
Recent filings
All 326 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2707:13 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-27 | 0001628280-26-067408 |
| 2026-10-2106:08 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-21 | 0001628280-26-066591 |
| 2026-10-2006:09 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-20 | 0001628280-26-066382 |
| 2026-09-1706:33 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-17 | 0001628280-26-062360 |
| 2026-09-1706:30 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-30 | 0001598599-26-000010 |
| 2026-09-1706:21 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-16 | 0001628280-26-062357 |
| 2026-09-1006:28 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-10 | 0001628280-26-061214 |
| 2026-09-0206:56 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-02 | 0001628280-26-059963 |
| 2026-08-1916:02 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-19 | 0001628280-26-057935 |
| 2026-08-1406:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-14 | 0001628280-26-056913 |
Latest annual report
Form 20-F for the fiscal year ended Dec 31, 2025Filed Apr 1, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1598599
- Tickers
- IPHA, IPHYF
- Exchange
- Nasdaq
- SIC code
- 2836 Biological Products, (No Diagnostic Substances)
- Sector
- Healthcare
- Fiscal year ends
- Dec 31
- Incorporated in
- I0
- Filer category
- Accelerated filer
- Former names
- Innate Pharma, SA (to 2014-01-31)
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 07:14 ET. Listed shows no prices and gives no investment advice.